KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2025)

Teva Pharmaceutical Industries' Equity Ratio history spans 17 years, with the latest figure at 0.19 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 41.9% year-over-year to 0.19, compared with a TTM value of 0.19 through Dec 2025, up 41.9%, and an annual FY2025 reading of 0.19, up 41.9% over the prior year.
  • Equity Ratio for Q4 2025 was 0.19 at Teva Pharmaceutical Industries, up from 0.18 in the prior quarter.
  • The five-year high for Equity Ratio was 0.24 in Q3 2021, with the low at 0.14 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.19, with a median of 0.19 recorded in 2025.
  • Year-over-year, Equity Ratio dropped 26.8% in 2024 and then soared 41.9% in 2025.
  • Tracing TEVA's Equity Ratio over 5 years: stood at 0.24 in 2021, then dropped by 17.18% to 0.2 in 2022, then dropped by 4.33% to 0.19 in 2023, then dropped by 26.8% to 0.14 in 2024, then surged by 41.9% to 0.19 in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Equity Ratio are 0.19 (Q4 2025), 0.18 (Q3 2025), and 0.17 (Q2 2025).